December 11, 2020 10:51 AM EST

Despite flopping pivotal trial, Novartis' Entresto will face adcomm firing line for holy grail heart failure patients

Kyle Blankenship

Novartis had big ideas for its heart-failure market leader Entresto in a highly sought-after patient population before a Phase III flop derailed its plans. But …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Despite flopping pivotal trial, Novartis' Entresto will face adcomm firing line for holy grail heart failure patients

Kyle Blankenship

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.

De­spite flop­ping piv­otal tri­al, No­var­tis' En­tresto will face ad­comm fir­ing line for holy grail heart fail­ure pa­tients

Kyle Blankenship

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Despite flopping pivotal trial, Novartis' Entresto will face adcomm firing line for holy grail heart failure patients

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Accelerated approval brings Pfizer's BRAF inhibitor to first-line patients

Exclusive: Florida cancer biotech raises $100M Series A

Califf, on his way out at FDA, predicts agency tug-of-war between Ramaswamy and RFK Jr.